Cutler Group LP Compass Pathways PLC Transaction History

Cutler Group LP

  • $307 Million
  • Q1 2024

A detailed history of Cutler Group LP transactions in Compass Pathways PLC stock. As of the latest transaction made, Cutler Group LP holds 2,070 shares of CMPS stock, worth $17,677. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,070
Previous 2,700 23.33%
Holding current value
$17,677
Previous $23,000 26.09%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 19, 2024
SELL
N/A
-630 Reduced 23.33%
2,070 $17,000
Q4 2023

Jan 18, 2024
SELL
N/A
-100 Reduced 3.57%
2,700 $23,000
Q3 2023

Nov 07, 2023
BUY
N/A
400 Added 16.67%
2,800 $20,000
Q2 2023

Jul 18, 2023
SELL
$7.79 - $10.69 $1,558 - $2,138
-200 Reduced 7.69%
2,400 $19,000
Q3 2022

Oct 25, 2022
SELL
$10.73 - $20.07 $836 - $1,565
-78 Reduced 2.91%
2,600 $27,000
Q2 2022

Aug 04, 2022
SELL
$6.76 - $14.18 $108,329 - $227,234
-16,025 Reduced 85.68%
2,678 $28,000
Q1 2022

Apr 14, 2022
SELL
$11.13 - $23.04 $20,134 - $41,679
-1,809 Reduced 8.82%
18,703 $241,000
Q4 2021

Jan 18, 2022
SELL
$21.81 - $48.96 $304,118 - $682,698
-13,944 Reduced 40.47%
20,512 $453,000
Q3 2021

Oct 26, 2021
BUY
$29.03 - $38.62 $505,180 - $672,065
17,402 Added 102.04%
34,456 $1.03 Million
Q2 2021

Jul 19, 2021
BUY
$32.29 - $39.68 $420,641 - $516,911
13,027 Added 323.49%
17,054 $650,000
Q1 2021

Apr 26, 2021
SELL
$34.75 - $57.5 $273,969 - $453,330
-7,884 Reduced 66.19%
4,027 $148,000
Q4 2020

Jan 21, 2021
BUY
$32.0 - $59.2 $381,152 - $705,131
11,911 New
11,911 $567,000

Others Institutions Holding CMPS

# of Institutions
144
Shares Held
29.3M
Call Options Held
156K
Put Options Held
563K
View Full List

About COMPASS Pathways plc

CMPS Quotes by TradingView
  • Ticker CMPS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Care Facilities
  • Shares Outstandng 42,522,400
  • Market Cap $363M
  • Description
  • COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. Th...
More about CMPS
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email